Eli Lilly (LLY) Q2 2025 earnings report
Hand Lilly On Thursday, he increased his guidance 2025 and published the second quarter earnings that made predictions on the weight loss and strong demand for diabetes drugs that broke box office records.
The company increased its 2025 financial sales guidance to $ 62 billion from the previous view of $ 58 billion in the underlying power in its business to 61 billion dollars. The Pharmaceutical Giant expects the regulated financial 2025 earnings to be between $ 21.75 and $ 23 from $ 20.78 to $ 22.28 per share.
Eli Lilly said that guidance reflects the existing tariffs of President Donald Trump as of August 7, but did not include the planned taxes on drugs imported to the USA.
In addition, on Thursday, Eli Lilly released long -awaited late -stage trial data about the experimental obesity pill Obesity pill, which helped patients to lose more than 12% of their body weight. This came under Wall Street’s expectations and reduced the company’s shares to 12% in pre -Sunday transactions on Thursday.
Eli Lilly CEO David Ricks, CNBC’s “Squawk Box”, “I feel good about the value of the company. Investors should decide what they think,” he said. “But Lilly is rolling and you are looking at rhythm and raising, a strong growth in the back half, we are excited for the future for our company and patients who need our products.”
The company’s diabetes therapy Mounjaro, over the expectations for the second quarter, earned approximately 5.2 billion dollars. This increased by 68% from the same period a year ago.
Eli Lilly’s weight loss of drugs Zepbound, defeating estimates, a quarter of $ 3.38 billion sales by making a sales of 172% of the year-olds increased.
According to StreetCount’s estimates, analysts expected Mounjaro and Zepbound to sell $ 4.49 billion and $ 3.06 billion, respectively.
“Mounjaro and Zepbound, which will be the best -selling medicine in the industry in the third year,” Mounjaro and Zepbound, “Mounjaro and Zepbound.” “And there’s much more to the pipeline.”
Eli Lilly’s second quarter of the Wall Street, based on a survey of LSEG’s analysts for the second quarter:
- Earning per share: $ 6,31 corrected and expected $ 5.57
- Revenues: 15.56 billion dollars and 14.71 billion dollars expected
The company has increased by 38% compared to the same period of the previous year and recorded the second quarter of $ 15.56 billion.
Sales in the US increased by 38% to 10.81 billion dollars. Eli Lilly said that with an increase of 46% in volume – or for its products, especially for products for Mounjaro and Zepbound – or the number of prescriptions or units sold. The company said that it was partially balanced with the realized prices of drugs.
The drug giant made a net revenue for the second quarter of $ 5.66 billion or $ 6.29 per share. This is compared to a net income a year ago by $ 2,97 billion or $ 3.28 per share.
Except for the value of intangible assets and other arrangements, Eli Lilly earned $ 6.31 per share for the second quarter.
The results are also Eli Lilly and other drug producers, while preparing for taxes on drugs imported to the United States and calling for lowering drug prices in the country.
President Eli sent letters to Lilly, and other companies called to take steps to reduce drug prices until September 29 last week. A controversial plan aimed at lowering drug costs by connecting the prices of some drugs in the United States to those with significantly low abroad in May came after signing a executive order that revives the “most preferred nation” policy.
